title: An investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability.
abstract: The aim of this study was to investigate the influence of experimental conditions on levothyroxine sodium release from two immediate-release tablet formulations which narrowly passed the standard requirements for bioequivalence studies. The in vivo study was conducted as randomised, single-dose, two-way cross-over pharmacokinetic study in 24 healthy subjects. The in vitro study was performed using various dissolution media, and obtained dissolution profiles were compared using the similarity factor value. Drug solubility in different media was also determined. The in vivo results showed narrowly passing bioequivalence. Considering that levothyroxine sodium is classified as Class III drug according to the Biopharmaceutics Classification System, drug bioavailability will be less sensitive to the variation in its dissolution characteristics and it can be assumed that the differences observed in vitro in some of investigated media probably do not have significant influence on the absorption process, as long as rapid and complete dissolution exists. The study results indicate that the current regulatory criteria for the value of similarity factor in comparative dissolution testing, as well as request for very rapid dissolution (more than 85% of drug dissolved in 15 min), are very restricted for immediate-release dosage forms containing highly soluble drug substance and need further investigation. The obtained results also add to the existing debate on the appropriateness of the current bioequivalence standards for levothyroxine sodium products.
authors: Galenika ad, Batajnicki drum BB, Belgrade, Serbia. ivana_kocic@yahoo.com
authors: Ivana
authors: I
authors: Kocic
authors: Irena
authors: I
authors: Homsek
authors: Mirjana
authors: M
authors: Dacevic
authors: Jelena
authors: J
authors: Parojcic
authors: Branislava
authors: B
authors: Miljkovic
mesh_terms: D000284:Administration, Oral; D000328:Adult; D019540:Area Under Curve; D001682:Biological Availability; D001702:Biopharmaceutics; D018592:Cross-Over Studies; D005260:Female; D006207:Half-Life; D006801:Humans; D008297:Male; D008875:Middle Aged; D012995:Solubility; D013607:Tablets; D013678:Technology, Pharmaceutical / Q000379:methods*; D013810:Therapeutic Equivalency; D013974:Thyroxine / Q000097:blood / Q000737:chemistry* / Q000493:pharmacokinetics*; D014284:Triiodothyronine / Q000097:blood
chemical_list: D013607:Tablets; D014284:Triiodothyronine; D013974:Thyroxine